Overview

A Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Healthy Participants and in Participants With CF

Status:
RECRUITING

Trial end date:
2026-03-30

Target enrollment:

Participant gender:

Summary

This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.

Phase:

PHASE1

Details

Lead Sponsor:

ReCode Therapeutics